Figure 7

PMS2 enhances caspase-3 activity in HeLa cells and improves cisplatin chemosensitivity. Cells were transfected with the PMS2 plasmid and followed by a treatment with cisplatin for 0-36 h. (A), Caspase-3 activity was shown to be significantly increased after administration of the PMS2 plasmid (2 μg/ml) in cisplatin-treated HeLa cells. (B), Effect of combined PMS2 and cisplatin on HeLa cells. The combination index (CI) demonstrated a strong synergistic anti-tumor activity at lower doses of the PMS2 plasmid (2-4 μg/ml) and cisplatin (4-10 μg/ml) treatment in HeLa cells for 24 h.